Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

✓ Free legal copy found

Preprint, hosted by europepmc.org

This is the authors’ own version from before peer review, so it may differ from the published paper.

Read the free PDF →

Other free copies

DOI: 10.1016/s0140-6736(16)32517-x · Publisher: Elsevier BV